Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.
BACKGROUND
The miR-212 was among the top differentially expressed miRNAs in pancreatic ductal adenocarcinoma (PDAC).


OBJECTIVE
The aim of this study was to investigate the expression of miR-212 in PDAC and evaluate its correlation with major clinicopathologic features and patients' survival.


METHODS
Fluorescence in situ hybridization (FISH) was adopted to examine miRNA expression in 45 pancreatic cancer and 20 normal pancreatic tissues. The relationship of miR-212 expression with clinicopathologic parameters and clinical outcome was evaluated.


RESULTS
miR-212 was confirmed to have significantly higher expression in PDAC compared with normal pancreatic tissues (51.1% vs 10%, p< 0.01). High expression of miR-212 was significantly associated with tumor size (p = 0.048) and tumor stage (p = 0.023). Moreover, in univariant analysis, patients with high expression of miR-212 demonstrate significantly poorer overall survival (p= 0.02).


CONCLUSIONS
High expression of miR-212 in PDAC is associated with shorter overall survival. It may be not only a potential prognostic marker, but also a possible therapeutic target in PDAC.
Zhengrong
Z
Wu
Liangjing
L
Zhou
Guoping
G
Ding
Liping
L
Cao
D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis
C551411:MIRN212 microRNA, human; D035683:MicroRNAs
Pancreatic neoplasms; Prognosis; microRNA-212